SCHEMBL14080945

SCHEMBL14080945

C[C@@H]1C[C@H](O)CCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369817 1.00
SCHEMBL6788556 1.00
SCHEMBL10211464 1.00
SCHEMBL18642668 1.00
Ethane SCHEMBL15059275 0.97 LMNA (0.32)
Methyl Alcohol SCHEMBL22770521 0.76
SCHEMBL31673150 0.76
SCHEMBL14476389 0.76
SCHEMBL11917825 0.76
SCHEMBL26279 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4647434-A1 MODULATOR FOR PROMOTING BINDING OF BUTYROPHILIN 3A1/2A1 Unicet Biotech Co., LLC (CN) 2025-11-12 EP disclosed
WO-2024146627-A1 MODULATOR FOR PROMOTING BINDING OF BUTYROPHILIN 3A1/2A1 北京清辉联诺生物科技有限责任公司 2024-07-11 WO disclosed
US-20230346951-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS YALE UNIVERSITY 2023-11-02 US disclosed
EP-3592741-B1 NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS PFIZER (US) 2023-02-15 EP disclosed
CN-111051304-B Imidazo [4,5-c ] quinoline derivatives as LRRK2 inhibitors 辉瑞大药厂 2022-12-27 CN disclosed
CN-111201226-B Cyclic substituted imidazo [4,5-c ] quinoline derivatives 辉瑞大药厂 2022-07-22 CN disclosed
US-11312713-B2 Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors PFIZER INC. (US) 2022-04-26 US disclosed
US-11312713-B2 Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors PFIZER INC. (US) 2022-04-26 US disclosed
EP-3592740-B1 CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES PFIZER (US) 2022-02-09 EP disclosed
EP-3592740-B1 CYCLIC SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE DERIVATIVES PFIZER (US) 2022-02-09 EP disclosed
US-10039753-B2 Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors PFIZER INC. (US) 2018-08-07 US disclosed
EP-3350178-A1 NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS Pfizer Inc (US) 2018-07-25 EP disclosed
WO-2017046675-A1 NOVEL IMIDAZO [4,5-C] QUINOLINE AND IMIDAZO [4,5-C][1,5] NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS PFIZER INC. (US) 2017-03-23 WO disclosed
WO-2017046675-A1 NOVEL IMIDAZO [4,5-C] QUINOLINE AND IMIDAZO [4,5-C][1,5] NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS PFIZER INC. (US) 2017-03-23 WO disclosed
US-20170073343-A1 Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors PFIZER INC. (US) 2017-03-16 US disclosed
US-20170073343-A1 Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors PFIZER INC. (US) 2017-03-16 US disclosed
US-20170073343-A1 Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors PFIZER INC. (US) 2017-03-16 US disclosed
US-20160368878-A1 REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-12-22 US disclosed
US-20160319322-A1 PATHOGEN DETECTION UNIVERSITY OF NOTRE DAME DU LAC (US) 2016-11-03 US disclosed
WO-2008115381-A1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2008-09-25 WO disclosed